The grant awarded for Chadli’s research focuses on a specific protein, UNC45A, that can be used as a promising novel immunotherapeutic target in treating triple-negative breast cancer (TNBC).
Understanding the role a certain molecule plays in both cancer cells, as well as the cells tasked to kill foreign invaders in the body, could be the key to unlocking the benefits of treatment for one of the most aggressive forms of breast cancer.